Stivarga
NICE recommends Bayer’s Stivarga for advanced hepatocellular carcinoma
November 29, 2018Sales and Marketing Bayer, NICE, Stivarga, UK, pharma
The National Institute for Health and Care Excellence (NICE) has voiced its recommendation for Bayer’s Stivarga (regorafenib) for use on …
NICE gives final draft guidance on two key cancer drugs
October 12, 2017Sales and Marketing Bayer, CDF, Cancer, Cancer Drugs Fund, Erivedge, NICE, Roche, Stivarga
NICE has announced it has published its final draft guidance for two cancer treatments, covering Bayer’s Stivarga (regorafenib) in the …
FDA approves first new drug for liver cancer in decade
April 28, 2017Medical Communications, Sales and Marketing Bayer, Stivarga, hepatocellular carcinoma, liver cancer
The FDA has announced that it has approved the first new treatment for hepatocellular carcinoma (HCC), a type of liver …
Bayer says its Stivarga improved overall survival in liver cancer in late-stage trials
June 30, 2016Research and Development, Sales and Marketing Bayer, Stivarga, drug trial, liver cancer
German pharma and crop sciences giant Bayer (ETR: BAYN) said late-stage trials for its drug to treat liver cancer showed a …
Bayer’s liver cancer drug meets primary endpoint in late stage trial
May 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Stivarga, late stage trial, liver cancer, phase III, regorafenib, trial
Bayer has announced positive results from a late-stage trial evaluating Stivarga (regorafenib) tablets for the treatment of patients with unresectable …
Merck and Eisai partner on cancer therapy trial
March 6, 2015Research and Development, Sales and Marketing Bayer, Cancer, FDA, Halaven, Lenvima, Merck, Stivarga, keytruda, oncology, pd1
Merck and Eisai are teaming up for collaborative trials to test the effects of using combinations of each company’s oncology …
New drugs give Bayer record sales
February 26, 2015Sales and Marketing Bayer, Eylea, Radium-223 chloride, Stivarga, Xarelto, adempas, aflibercept, dekkers, german, regorafenib, riociguat, xofigo
Bayer has reported strong financial results for 2014 driven primary by sales of new medicines, although controversy surrounding its anti-clotting …
Xarelto lift for Bayer
March 3, 2014Manufacturing and Production, Sales and Marketing Bayer, Eylea, Stivarga, Xarelto, blood thinner, xofigo
Bayer Group says sales of its blood thinner Xarelto will be higher than it had predicted, with peak annual sales …
Sanofi’s Zaltrap data published
October 8, 2012Research and Development, Sales and Marketing Erbitux, Sanofi, Stivarga, Zaltrap, avastin
Detailed data from the Phase III trial of Sanofi’s newly-licenced anti-VEGF cancer drug Zaltrap, co-marketed with Regeneron, has been published. …
FDA approves Bayer’s Stivarga
October 1, 2012Research and Development, Sales and Marketing Bayer, FDA, KRAS, Roche, Stivarga, avastin
The FDA has approved Bayer HealthCare’s oncology pill Stivarga to treat patients with metastatic colorectal cancer (mCRC) whose disease has …
Latest content
FibroFind appoints Lee Borthwick as CEO
